Dr. Evgenyi Shalaev, Allergan - Qepler Summits And Conferences

Dr. Evgenyi Shalaev

Executive Director
Irvine, California, USA

Evgenyi Shalaev, Ph.D., AAPS Fellow, is an executive director in Pharmaceutical Development, Allergan plc, Irvine, California, USA, and an adjunct professor in the Department of Pharmaceutics, University of Minnesota.

Dr. Shalaev held the Royal Society Fellowship in Pafra Biopreservation and the University of Cambridge, UK, postdoctoral research appointments at the University of Wisconsin-Madison and Cornell University, and worked at the Institute of Carbon (Russia), Institute of Molecular Biology (Russia), and Pfizer Inc. (USA), before taking his present position.

His responsibilities in Allergan are focused on biological drug products covering both controlled release dosage forms and conventional formulations such as solutions and freeze-dried powders.

Dr Shalaev’s research interests include: amorphous and other disordered solids; phase transitions in aqueous systems during freezing and drying; chemical and physical stability of small molecules and biologicals; development and scale-up of freeze-drying processes. He has published over a hundred peer-reviewed papers, book chapters, and patent applications.

Related Sessions:

2nd Annual Pharmaceutical
Lyophilization Summit 2020

Discuss best practices in tech & regulatory updates, process, formulation, testing, monitoring, new products development.
  • 12 Feb 2020
  • Berlin, DE
  • Pharma
Day 1: Wednesday, 12 February 2020
CASE STUDY: Crystallization during freezing and drying: practical importance and characterization methods.
  • Many excipients and active pharmaceutical ingredients can crystallize during freezing and freeze-drying
  • Crystallization behavior depends on multiple factors, e.g., the nature of a particular molecule, presence and concentration of other solutes, and freezing/annealing conditions
  • Crystallization can be either beneficial (e.g., bulking agent), or detrimental (e.g., cryo/lyoprotector) for manufacturing process efficiency and the product quality
  • Analytical methods to monitor crystallization on both small scale (e.g., DSC and low-temperature X-ray diffraction) and in-situ during manufacture (e.g., heat flux sensors) are discussed
View Details